These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11326167)

  • 21. [Circulating prostatic-specific antigen in benign hypertrophy and localized prostate cancer: can PSA be considered a screening examination for localized cancer?].
    Perrin P; Francois O; Maquet JH; Bringeon G; Duteil P; Devonec M
    Prog Urol; 1991 Jun; 1(3):419-31. PubMed ID: 1726943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rural residence and prostate cancer screening with prostate-specific antigen.
    Stamatiou K; Skolarikos A
    Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of screening on prostate cancer rates and trends.
    Mettlin C
    Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-specific antigen screening and mortality from prostate cancer.
    Marcella SW; Rhoads GG; Carson JL; Merlino F; Wilcox H
    J Gen Intern Med; 2008 Mar; 23(3):248-53. PubMed ID: 18172740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
    Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
    Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
    Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
    Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer screening at an equal access tertiary care center: its impact 10 years after the introduction of PSA.
    Soderdahl DW; Hernandez J
    Prostate Cancer Prostatic Dis; 2002; 5(1):32-5. PubMed ID: 15195128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R; Gulati R; Falcon S; Penson DF
    Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen and prostate cancer mortality: a systematic review.
    Wallner LP; Jacobsen SJ
    Am J Prev Med; 2013 Sep; 45(3):318-26. PubMed ID: 23953359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate cancer screening.
    Sikaris K
    Pathology; 2012 Feb; 44(2):99-109. PubMed ID: 22198258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term prostate-specific antigen contamination in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Luján M; Páez Á; Angulo JC; Granados R; Nevado M; Torres GM; Berenguer A
    Actas Urol Esp; 2016 Apr; 40(3):164-72. PubMed ID: 26620123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Finnish prostate cancer screening trial: analyses on the screening failures.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    Int J Cancer; 2015 May; 136(10):2437-43. PubMed ID: 25359457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial results did not resolve controversies surrounding prostate cancer screening.
    Hoffman RM
    Curr Opin Urol; 2010 May; 20(3):189-93. PubMed ID: 20224414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study.
    Rowe EW; Laniado ME; Walker MM; Patel A
    BJU Int; 2005 Jun; 95(9):1249-52. PubMed ID: 15892810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate cancer mortality in the Finnish randomized screening trial.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on screening for prostate cancer with prostate-specific antigen.
    Schmid HP; Riesen W; Prikler L
    Crit Rev Oncol Hematol; 2004 Apr; 50(1):71-8. PubMed ID: 15094160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.